Platelet antiaggregants in primary and secondary prevention of atherothrombotic events;Antiagregantes plaquetários na prevenção primária e secundária de eventos aterotrombóticos

Arquivos Brasileiros de Cardiologia

Volumn 100, Issue 6, 2013, Pages

  Silva, Marcos Vinícius Ferreira ^a   Dusse, Luci Maria SantAna ^a   Vieira, Lauro Mello ^a   Carvalho, Maria das Graças ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Angina pectoris; Aspirin; Coronary artery disease prevention and control; Myocardial infarction; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; CLOPIDOGREL; DIPYRIDAMOLE; ELINOGREL; METOPROLOL; PLACEBO; PRASUGREL; TICAGRELOR; TICLOPIDINE; VORAPAXAR;

ALLERGIC REACTION; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; GASTROINTESTINAL HEMORRHAGE; GENDER; HEADACHE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH EROSION; THROMBOSIS;

ASPIRIN; ATHEROSCLEROSIS; CORONARY THROMBOSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 84880383964     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20130122     Document Type: Article

References (25)

1. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25(14):1197-207.
2. Organização Mundial da Saúde (OMS). [citado 2012 abril 10]. Disponível em: url: http://www.who.int
3. thedition). Chest. 2008;133(6 Suppl):199S-233S.
4. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30(16):1964-77.
5. a ed. Rio de Janeiro: Guanabara Koogan; 2010.
6. Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol. 2006;147 Suppl 1:S241-51.
7. Michelson AD. Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program. 2011;2011:62-9.
8. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther. 2003;307(3):969-76.
9. Tello-Montoliu A, Tomasello SD, Ueno M, Angiolillo DJ. Antiplatelet therapy: thrombin receptor antagonists. Br J Clin Pharmacol. 2011;72(4):658-71.
10. Mackman N. Triggers, targets and treatment for thrombosis. Nature. 2008;451(7181):914-8.
11. Dai Y, Ge J. Clinical use of aspirin in treatment and prevention of cardiovascular disease. Thrombosis. 2012;2012:245037.
12. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373(9678):1849-60.
13. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306-13.
14. Bollati M, Gaita F, Anselmino M. Antiplatelet combinations for prevention of atherothrombotic events. Vasc Health Risk Manag. 2011;7:23-30.
15. Faxon DP, Nesto RW. Antiplatelet therapy in populations with high risk of atherothrombosis. J Natl Med Assoc. 2006;98(5):711-21.
16. Eshaghian S, Shah PK, Kaul S. Advances in antiplatelet treatment for acute coronary syndromes. Heart. 2010;96(9):656-61.
17. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Circulation. 2010;121(23):2575-83.
18. Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs. 2007;7(4):289-97.
19. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. Erratum in BMJ. 2002;324(7330):141.
20. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23):2922-32.
21. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100(9):1261-75.
22. Steg PG, Dorman SH, Amarenco P. Atherothrombosis and the role of antiplatelet therapy. J Thromb Haemost. 2011;9 Suppl 1:325-32.
23. Marczewski MM, Postula M, Kosior D. Novel antiplatelets agents in the prevention of cardiovascular complications-focus on ticagrelor. Vasc Health Risk Manag. 2010;6:419-29.
24. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011;112(2):292-318.
25. White HD. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. Am Heart J. 2011;161(3):450-461. Erratum in Am Heart J. 2011;162(3):569.